Skip to main content

Rate your conversation

Thanks for the feedback!

Skip to main content

For questions about financial assistance,
call 1-844-DUPIXENT, option 1 or
click to learn more  

  • SELECT CONDITION
    • Moderate-to-Severe Eczema (Ages 6+ Months)
    • Moderate-to-Severe Asthma (Ages 6+ Years)
    • Chronic Obstructive Pulmonary Disease
      (Ages 18+ Years)
    • Chronic Rhinosinusitis with Nasal Polyps
      (Ages 12+ Years)
    • Eosinophilic Esophagitis (Ages 1+ Years,
      who weigh at least 33 lb (15 kg))
    • Prurigo Nodularis (Ages 18+ Years)
    • Chronic Spontaneous Urticaria (Ages 12+ Years)
  • Choose Your
    Language
    • Español
    • Página de inicio de franquicias
    • Eczema moderado a grave (6 meses de edad o más)
    • Asma moderada a grave (6 años de edad o más)
    • Rinosinusitis crónica con pólipos nasales (12 años de edad o más)

    • 中文
    • 中文網站
  • Prescribing & Patient
    Information
    • PATIENT INFORMATION
    • Patient Information - English
    • Patient Information - Spanish

    • PRESCRIBING INFORMATION
    • Prescribing Information - English
    • Prescribing Information - Spanish

    • PRE-FILLED SYRINGE INSTRUCTIONS FOR USE
    • 200 mg Syringe - English
    • 200 mg Syringe - Spanish
    • 300 mg Syringe - English
    • 300 mg Syringe - Spanish

    • PRE-FILLED PEN INSTRUCTIONS FOR USE
    • 200 mg Pen - English
    • 200 mg Pen - Spanish
    • 300 mg Pen - English
    • 300 mg Pen - Spanish
  • For Healthcare
    Professionals
  • Copay
    Offer
  • FOR U.S. RESIDENTS ONLY
Dupixent® (dupilumab) Injection (200 mg or 300 mg) Logo
  • PATIENT SUPPORT,
    COST & SAVINGS
    • Copay Card
    • Pricing and Insurance
    • Patient Support Program
  • Taking
    Dupixent
    • Injection Support Center
    • Traveling With DUPIXENT
  • FREQUENTLY
    ASKED QUESTIONS
  • CHOOSE YOUR LANGUAGE
    • Español
    • Página de inicio de franquicias
    • Eczema moderado a grave
      (6 meses de edad o más)
    • Asma moderada a grave
      (6 años de edad o más)
    • Rinosinusitis crónica con pólipos nasales
      (12 años de edad o más)

    • 中文
    • 中文網站
  • For Healthcare Professionals
  • Copay Offer

Important Safety Information and Indications

Do not use if you are allergic to dupilumab or to any of the ingredients in DUPIXENT®.

Before using DUPIXENT, tell your healthcare provider about all your medical conditions, including if you:

  • have eye problems.
  • have a parasitic (helminth) infection.
  • are scheduled to receive any vaccinations. You should not receive a “live vaccine” right before and during treatment with DUPIXENT.
  • are pregnant or plan to become pregnant. It is not known whether DUPIXENT will harm your unborn baby.
    • A pregnancy registry for women who take DUPIXENT during pregnancy collects information about the health of you and your baby. To enroll or get more information call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/.
  • are breastfeeding or plan to breastfeed. It is not known whether DUPIXENT passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Especially tell your healthcare provider if you are taking oral, topical, or inhaled corticosteroid medicines; have asthma and use an asthma medicine; or have atopic dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, chronic obstructive pulmonary disease or chronic spontaneous urticaria, and also have asthma. Do not change or stop your other medicines, including corticosteroid medicine or other asthma medicine, without talking to your healthcare provider. This may cause other symptoms that were controlled by those medicines to come back.

DUPIXENT can cause serious side effects, including:

  • Allergic reactions. DUPIXENT can cause allergic reactions that can sometimes be severe. Stop using DUPIXENT and tell your healthcare provider or get emergency help right away if you get any of the following signs or symptoms: breathing problems or wheezing, swelling of the face, lips, mouth, tongue or throat, fainting, dizziness, feeling lightheaded, fast pulse, fever, hives, joint pain, general ill feeling, itching, skin rash, swollen lymph nodes, nausea or vomiting, or cramps in your stomach-area.
  • Eye problems. Tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision, such as blurred vision. Your healthcare provider may send you to an ophthalmologist for an exam if needed.
  • Inflammation of your blood vessels. Rarely, this can happen in people with asthma who receive DUPIXENT. This may happen in people who also take a steroid medicine by mouth that is being stopped or the dose is being lowered. Tell your healthcare provider right away if you have: rash, chest pain, worsening shortness of breath, brown or dark colored urine, persistent fever, or a feeling of pins and needles or numbness of your arms or legs.
  • Psoriasis. This can happen in people with atopic dermatitis and asthma who receive DUPIXENT. Tell your healthcare provider about any new skin symptoms. Your healthcare provider may send you to a dermatologist for an examination if needed. 
  • Joint aches and pain. Some people who use DUPIXENT have had trouble walking or moving due to their joint symptoms, and in some cases needed to be hospitalized. Tell your healthcare provider about any new or worsening joint symptoms. Your healthcare provider may stop DUPIXENT if you develop joint symptoms.

The most common side effects include:

  • Eczema: injection site reactions, eye and eyelid inflammation, including redness, swelling, and itching, sometimes with blurred vision, dry eye, cold sores in your mouth or on your lips, and high count of a certain white blood cell (eosinophilia).
  • Asthma: injection site reactions, high count of a certain white blood cell (eosinophilia), pain in the throat (oropharyngeal pain), and parasitic (helminth) infections.
  • Chronic Rhinosinusitis with Nasal Polyps: injection site reactions, eye and eyelid inflammation, including redness, swelling, and itching, sometimes with blurred vision, high count of a certain white blood cell (eosinophilia), gastritis, joint pain (arthralgia), trouble sleeping (insomnia), and toothache.
  • Eosinophilic Esophagitis: injection site reactions, upper respiratory tract infections, cold sores in your mouth or on your lips, and joint pain (arthralgia).
  • Prurigo Nodularis: eye and eyelid inflammation, including redness, swelling, and itching, sometimes with blurred vision, herpes virus infections, common cold symptoms (nasopharyngitis), dizziness, muscle pain, and diarrhea.
  • Chronic Obstructive Pulmonary Disease: injection site reactions, common cold symptoms (nasopharyngitis), high count of a certain white blood cell (eosinophilia), viral infection, back pain, inflammation inside the nose (rhinitis), diarrhea, gastritis, joint pain (arthralgia), toothache, headache, and urinary tract infection.
  • Chronic Spontaneous Urticaria: injection site reactions.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of DUPIXENT. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Use DUPIXENT exactly as prescribed by your healthcare provider. It’s an injection given under the skin (subcutaneous injection). Your healthcare provider will decide if you or your caregiver can inject DUPIXENT. Do not try to prepare and inject DUPIXENT until you or your caregiver have been trained by your healthcare provider. In children 12 years of age and older, it’s recommended DUPIXENT be administered by or under supervision of an adult. In children 6 months to less than 12 years of age, DUPIXENT should be given by a caregiver.

Please see accompanying adjacent links for full Prescribing Information including Patient Information.

Indications

DUPIXENT is a prescription medicine used:

  • to treat adults and children 6 months of age and older with moderate-to-severe eczema (atopic dermatitis or AD) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. DUPIXENT can be used with or without topical corticosteroids. It is not known if DUPIXENT is safe and effective in children with atopic dermatitis under 6 months of age.
  • with other asthma medicines for the maintenance treatment of moderate-to-severe eosinophilic or oral steroid dependent asthma in adults and children 6 years of age and older whose asthma is not controlled with their current asthma medicines. DUPIXENT helps prevent severe asthma attacks (exacerbations) and can improve your breathing. DUPIXENT may also help reduce the amount of oral corticosteroids you need while preventing severe asthma attacks and improving your breathing. It is not known if DUPIXENT is safe and effective in children with asthma under 6 years of age.
  • with other medicines for the maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults and children 12 years of age and older whose disease is not controlled. It is not known if DUPIXENT is safe and effective in children with chronic rhinosinusitis with nasal polyps under 12 years of age.
  • to treat adults and children 1 year of age and older with eosinophilic esophagitis (EoE), who weigh at least 33 pounds (15 kg). It is not known if DUPIXENT is safe and effective in children with eosinophilic esophagitis under 1 year of age, or who weigh less than 33 pounds (15 kg).
  • to treat adults with prurigo nodularis (PN). It is not known if DUPIXENT is safe and effective in children with prurigo nodularis under 18 years of age.
  • with other medicines for the maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and a high number of blood eosinophils (a type of white blood cell that may contribute to your COPD). DUPIXENT is used to reduce the number of flare-ups (the worsening of your COPD symptoms for several days) and can improve your breathing. It is not known if DUPIXENT is safe and effective in children with chronic obstructive pulmonary disease under 18 years of age.
  • to treat adults and children 12 years of age and older with chronic spontaneous urticaria (CSU)  who continue to have hives that are not controlled with H1 antihistamine treatment. It is not known if DUPIXENT is safe and effective in children with chronic spontaneous urticaria under 12 years of age, or who weigh less than 66 pounds (30 kg). 

DUPIXENT is not used to relieve sudden breathing problems and will not replace an inhaled rescue medicine.

DUPIXENT is not used to treat any other forms of hives (urticaria). 

Sanofi® Logo

Regeneron® Logo

Site Map
Legal Disclaimer Information

Questions or comments?
Contact Sanofi US or Regeneron Pharmaceuticals, Inc. or call 1-844-387-4936
to contact DUPIXENT MyWay®.

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.
DUPIXENT® and DUPIXENT MyWay® are registered trademarks of Sanofi Biotechnology.
 

Sanofi US is hosting this website on behalf of Sanofi and Regeneron Pharmaceuticals, Inc.

Sanofi and Regeneron are industry partners, who are committed to handling personal data in ways that respect your privacy. Both companies may independently process your personal data to manage patient support programs and product marketing campaigns. Please refer to Regeneron's Privacy Notice and Consumer Health Data Privacy Policy and Sanofi’s Privacy Policy and Consumer Health Data Privacy Policy and Cookies Policy for more information regarding processing of your personal data.

Are you sure you want to leave?

Please note: By clicking on this link, you will be leaving this Sanofi-hosted US website and going to another, entirely independent website. Sanofi US and Regeneron provide these links as a service to their website visitors and users; however, they take no responsibility for the information on any website but their own.

This DUPIXENT® (dupilumab) website is for U.S. healthcare professionals only. Click "continue" only if you are a U.S. healthcare professional.

US-DAS-1231(1)

Estás a punto de abandonar este sitio para visitar nuestro sitio en inglés. Haz clic en "Continuar" si quieres proseguir.

US-DAS-1231(1)

Enter your email address and we will send you your requested resource.

Success!

Your email is on its way. Be sure to check your inbox.